Bergs Securities acted as sole manager and bookrunner to Initiator Pharma Therapeutics in its SEK 56 million rights issue

Corporate Finance

Bergs Securities acted as sole manager and bookrunner to Initiator Pharma Therapeutics in its SEK 56 million rights issue.

Initiator Pharma is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma ’s lead project is pudafensine, where the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial.

Share

More News

Related News

Certified Adviser
Bergs Securities is proud to have acted as certified adviser and financial advisor to AIRA in its application to list its shares on Nasdaq First North Growth Market.
Corporate Finance
Bergs Securities acted as financial adviser and sole bookrunner to Medclair in its SEK 23 million directed share issue to Eiffel Investment Group
Corporate Finance
Bergs Securities acted as Sole Manager to Observit in its SEK 26 million directed share issue to Eiffel Investment Group
More News